Zaprinast, solid

Zaprinast, solid

Application

Zaprinast has been used to determine its inhibitory effect on the meiosis of oocytes by germinal vesicle breakdown (GVBD) assay and to test the inhibitory effect of it on the retinal cells by immunohistochemistry.

Biochem/physiol Actions

Selective inhibitor of cGMP-specific phosphodiesterases V and VI (PDE5/6) and an agonist at the G protein-coupled receptor 35 (GPR35).

Zaprinast insubstantially inhibits phosphodiesterase 10 and 11 (PDE10 and PDE11). It also exhibits vasodilating effects.

Packaging

25, 100 mg in poly bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Solubility Form Price Quantity
2794307 Zaprinast, solid white 200 REZGGXNDEMKIQB-UHFFFAOYSA-N 1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19) DMSO: 10 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.11 mg/mL, H2O: insoluble solid
£403.93 (exc VAT) per 100MG
-
+
2794308 Zaprinast, solid white 200 REZGGXNDEMKIQB-UHFFFAOYSA-N 1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19) DMSO: 10 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.11 mg/mL, H2O: insoluble solid
£117.56 (exc VAT) per 25MG
-
+